Expert Interview
A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Ticker(s): NVO, LLYInstitution: Massachussets General Hospital
- Director of Dialysis Services and the Medical Director Emerita of the Renal and Pancreas Transplantation at Massachusetts General Hospital; Professor of Medicine at Harvard Medical School.
- Treats approximately 15 patients with IgA Nephropathy.
- Research focus is on defining effective antirejection therapy directed against the T cell in both the efficacy of antithymocyte globulin (ATG) as well as the first human trials of the monoclonal antibody OKT3; Clinical focus on acute and chronic renal failure, Kidney transplants, UTIs and dialysis.
How many patients do you currently treat with CKD?
- What percent of those typically also have Type 2 diabetes?
What do you think about the individual components of the FLOW trial's composite endpoint and what are you looking for in terms of when they announce the details?
Added By: sara_adminDo you think this drug could delay the onset of dialysis and what do you think about its mechanism of action?
Added By: sara_adminTo what extent would the impact of this drug on nephrologists prescribing it change if patients are already getting Ozempic to manage their diabetes?
Added By: sara_adminWas there a similar scenario with nephrologists prescribing SGLT2 inhibitors for diabetic patients?
Added By: sara_adminWhat would be a meaningful difference in terms of the EGFR endpoint in the FLOW trial?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
